As Holder of Common Stock Purchase Warrants of Cancer Genetics, Inc.Cancer Genetics, Inc • November 20th, 2020 • Services-medical laboratories • New York
Cancer Genetics, Inc. (the “Company”) desires to amend the Securities Purchase Agreement, dated as of May 19, 2016, between the Company and the purchasers signatory thereto (the “May 2016 Purchase Agreement”) and the Securities Purchase Agreement, dated as of September 8, 2016, between the Company and the purchasers signatory thereto pursuant to which the Company issued the Exchange Warrants (as defined below) (the “September 2016 Purchase Agreement” and, collectively with the May 2016 Purchase Agreement, the “Purchase Agreements” and, each, a “Purchase Agreement”). Each Purchase Agreement provides that it may be modified and amended in a written instrument signed by the Company and holders of at least 67% of the issuable Warrant Shares (as defined in the respective Purchase Agreements).
